These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 35403533)

  • 1. Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
    Rizzo A; Cusmai A; Gadaleta-Caldarola G; Palmiotti G
    Expert Rev Gastroenterol Hepatol; 2022 Apr; 16(4):333-339. PubMed ID: 35403533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?
    Rizzo A; Ricci AD
    Expert Opin Investig Drugs; 2022 Apr; 31(4):415-423. PubMed ID: 34429006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
    Rizzo A; Ricci AD; Di Federico A; Frega G; Palloni A; Tavolari S; Brandi G
    Front Oncol; 2021; 11():803133. PubMed ID: 34976841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers for response to immunotherapy in hepatobiliary malignancies.
    Lin ZF; Qin LX; Chen JH
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):413-419. PubMed ID: 35973935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
    Chan LL; Chan SL
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):39-52. PubMed ID: 33724135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Bai J; Liang P; Li Q; Feng R; Liu J
    Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer.
    Rizzo A; Ricci AD; Brandi G
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma.
    Muhammed A; D'Alessio A; Enica A; Talbot T; Fulgenzi CAM; Nteliopoulos G; Goldin RD; Cortellini A; Pinato DJ
    Expert Rev Mol Diagn; 2022 Mar; 22(3):253-264. PubMed ID: 35236211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy.
    Nikoo M; Hassan ZF; Mardasi M; Rostamnezhad E; Roozbahani F; Rahimi S; Mohammadi J
    Pathol Res Pract; 2023 Jul; 247():154473. PubMed ID: 37207558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond.
    Rizzo A; Ricci AD
    Expert Opin Investig Drugs; 2022 Jun; 31(6):549-555. PubMed ID: 34793275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges.
    Rizzo A; Ricci AD; Gadaleta-Caldarola G; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1245-1251. PubMed ID: 34431725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver.
    Hewitt DB; Rahnemai-Azar AA; Pawlik TM
    Expert Opin Investig Drugs; 2021 Aug; 30(8):827-835. PubMed ID: 34102935
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.
    Guardascione M; Toffoli G
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
    Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma.
    Zhu Y; Qin LX
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):420-429. PubMed ID: 35977874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review.
    Reiter FP; Ben Khaled N; Ye L; Zhang C; Seidensticker M; Op den Winkel M; Denk G; Geier A; De Toni EN
    Dig Dis; 2022; 40(5):565-580. PubMed ID: 34644705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
    Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
    JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.